GBT’s first 3D, Multiplanar Microchip Continuation Patent Granted

GBT’s first 3D, Multiplanar Microchip Continuation Patent Granted

GBT Technologies Inc. ( OTC PINK: GTCH ) (“GBT” or the “Company”), first 3D, Multi-Planar IC design and manufacturing technology, continuation patent, was granted by the United States Patent and Trademark Office (“USPTO”) on August 9, 2022.

The first continuation patent is focused on strengthening the new microchip’s design and manufacturing concepts and methodologies. A second continuation patent was filed on July 29, 2022, seeking to protect the memory integrated circuit’s architecture and connectivity structures. The original nonprovisional patent protects a system and method to design and manufacture microchips on multi-plane surfaces, enabling placing more electronic circuits on chips, with the goal of enabling faster performance and better electrical characteristics.

Picture of admin

admin

Leave a Replay

Related Posts

Sign up for our Newsletter

if you want to keep…. to our newsletter or follow our social media

DISCLAIMER: Certain statements contained in this website may constitute forward-looking statements Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors. The forward-looking statements included in this website represent the Company’s views as of the date of this release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the release.